Corcept Therapeutics | CORT - Interest Expense On Debt


Corcept Therapeutics reported $1.03B in Interest Expense on Debt for its fiscal quarter ending in September of 2026.





Interest Expense On Debt Change Date
Acadia Pharmaceuticals USD 0 4.12M Sep/2024
Alaunos Therapeutics USD 1.07M 215K Jun/2023
ANI Pharmaceuticals USD 3.06M 580K Sep/2026
Ardelyx USD 4.96M 642K Jun/2026
Aurora Cannabis CAD 464K 234K Jun/2026
BioMarin Pharmaceutical USD 55.63M 7.67M Sep/2026
Bristol-Myers Squibb USD 403M 4M Sep/2026
Canopy Growth CAD 12.68M 364K Jun/2026
Corcept Therapeutics USD 1.03B 145.32M Sep/2026
Eli Lilly USD 316M 201.3M Sep/2026
J&J USD 43M 25M Mar/2026
Knight Therapeutics CAD 3.92M 1.56M Dec/2025
Lexicon Pharmaceuticals USD 2.03M 124K Dec/2025
Merck USD 525M 46M Jun/2026
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Novartis USD 468M 6M Sep/2026
Novartis USD 281M 8M Sep/2025
Omeros USD 4.05M 5.16M Sep/2024
Pacira USD 112.4M 108.78M Sep/2026
Pfizer USD 662M 5M Sep/2026
Supernus Pharmaceuticals USD 718K 1.6M Sep/2026
TG Therapeutics USD 15.82M 753K Sep/2026